Nuveen Asset Management, LLC Immunovant, Inc. Transaction History

Nuveen Asset Management, LLC

$340 Billion
Q4 2024

A detailed history of Nuveen Asset Management, LLC transactions in Immunovant, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 915,151 shares of IMVT stock, worth $25.2 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

915,151

Previous 1,104,910 17.17%

Holding current value

$25.2 Million

Previous $30.4 Million 17.18%

% of portfolio

0.01%

Previous 0.01%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	N/A	-189,759 Reduced 17.17%	915,151 $25.2 Million
Q3 2024 Nov 14, 2024	SELL	$27.51 - $27.51 $1.1 Million - $1.1 Million	-39,939 Reduced 3.49%	1,104,910 $30.4 Million
Q2 2024 Aug 09, 2024	BUY	$25.1 - $31.61 $1.02 Million - $1.28 Million	40,571 Added 3.67%	1,144,849 $30.2 Million
Q1 2024 May 13, 2024	SELL	$30.27 - $43.79 $3.72 Million - $5.39 Million	-122,988 Reduced 10.02%	1,104,278 $35.7 Million
Q4 2023 Feb 14, 2024	BUY	$31.31 - $44.19 $6.23 Million - $8.8 Million	199,050 Added 19.36%	1,227,266 $51.7 Million
Q3 2023 Nov 14, 2023	BUY	$18.55 - $39.96 $4.47 Million - $9.63 Million	240,965 Added 30.61%	1,028,216 $39.5 Million
Q2 2023 Aug 14, 2023	BUY	$14.2 - $23.75 $3.76 Million - $6.29 Million	264,855 Added 50.7%	787,251 $14.9 Million
Q1 2023 May 15, 2023	BUY	$15.27 - $19.72 $3.03 Million - $3.91 Million	198,478 Added 61.27%	522,396 $8.1 Million
Q4 2022 Feb 14, 2023	BUY	$6.59 - $17.75 $958,779 - $2.58 Million	145,490 Added 81.54%	323,918 $5.75 Million
Q3 2022 Nov 14, 2022	SELL	$3.93 - $6.37 $12,139 - $19,676	-3,089 Reduced 1.7%	178,428 $995,000
Q2 2022 Aug 15, 2022	SELL	$3.38 - $5.65 $140,499 - $234,859	-41,568 Reduced 18.63%	181,517 $708,000
Q1 2022 May 16, 2022	SELL	$5.06 - $8.77 $753,256 - $1.31 Million	-148,865 Reduced 40.02%	223,085 $1.32 Million
Q4 2021 Feb 14, 2022	BUY	$7.33 - $9.32 $92,673 - $117,832	12,643 Added 3.52%	371,950 $3.17 Million
Q3 2021 Nov 12, 2021	SELL	$7.01 - $11.37 $266,905 - $432,912	-38,075 Reduced 9.58%	359,307 $3.12 Million
Q2 2021 Aug 16, 2021	BUY	$9.4 - $16.85 $293,270 - $525,703	31,199 Added 8.52%	397,382 $4.2 Million
Q1 2021 May 17, 2021	SELL	$13.08 - $49.6 $778,037 - $2.95 Million	-59,483 Reduced 13.97%	366,183 $5.87 Million
Q4 2020 May 17, 2021	SELL	$36.36 - $52.71 $722,145 - $1.05 Million	-19,861 Reduced 4.46%	425,666 $19.7 Million
Q4 2020 Feb 16, 2021	BUY	$36.36 - $52.71 $3.22 Million - $4.67 Million	88,547 Added 24.8%	445,527 $20.6 Million
Q3 2020 Nov 16, 2020	BUY	$22.61 - $38.9 $3.79 Million - $6.53 Million	167,829 Added 88.73%	356,980 $12.6 Million
Q2 2020 Aug 14, 2020	BUY	$13.87 - $28.44 $2.62 Million - $5.38 Million	189,151 New	189,151 $4.61 Million

Others Institutions Holding IMVT

# of Institutions

218

Shares Held

67.1M

Call Options Held

2.48M

Put Options Held

561K

View Full List

About Immunovant, Inc.

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

More about IMVT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.

Account

Nuveen Asset Management, LLC Immunovant, Inc. Transaction History